Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure.

Miyashita Y, Nishimura R, Nemoto M, Matsudaira T, Kurata H, Yokota T, Yokota K, Tojo K, Utsunomiya K, Tajima N.

Cardiovasc Diabetol. 2008 May 29;7:16.

PMID: 18507868 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.

Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.

Rom J Intern Med. 2003;41(2):153-62.

PMID: 15526500 [PubMed - indexed for MEDLINE]

Related Articles

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.

PMID: 18158076 [PubMed - indexed for MEDLINE]

Related Articles

A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.

Jacober SJ, Scism-Bacon JL, Zagar AJ.

Diabetes Obes Metab. 2006 Jul;8(4):448-55.

PMID: 16776752 [PubMed - indexed for MEDLINE]

Related Articles

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.

Diabetes Care. 1998 Apr;21(4):574-9.

PMID: 9571345 [PubMed - indexed for MEDLINE]

Related Articles

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID: 18158078 [PubMed - indexed for MEDLINE]

Related Articles

Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.

Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.

Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):527-32.

PMID: 17115351 [PubMed - indexed for MEDLINE]

Related Articles

Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.

Schiel R, Müller UA.

Exp Clin Endocrinol Diabetes. 2007 Nov;115(10):627-33.

PMID: 18058596 [PubMed - indexed for MEDLINE]

Related Articles

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.

Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT.

Diabetes Care. 1997 Apr;20(4):597-606.

PMID: 9096986 [PubMed - indexed for MEDLINE]

Related Articles

Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.

Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Harman-Boehm I.

Clin Ther. 2003 Dec;25(12):3109-23.

PMID: 14749149 [PubMed - indexed for MEDLINE]

Related Articles

Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.

Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, Levin S, Nuttall F, Sawin C, Silbert C, Lee HS, Johnson-Nagel N.

Diabetes Care. 1996 Dec;19(12):1375-81.

PMID: 8941467 [PubMed - indexed for MEDLINE]

Related Articles

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC; 4-T Study Group.

N Engl J Med. 2007 Oct 25;357(17):1716-30. Epub 2007 Sep 21.

PMID: 17890232 [PubMed - indexed for MEDLINE]

Related Articles

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID: 15099124 [PubMed - indexed for MEDLINE]

Related Articles

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.

PMID: 7587846 [PubMed - indexed for MEDLINE]

Related Articles

Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).

Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.

Diabetes Obes Metab. 2006 Jan;8(1):58-66.

PMID: 16367883 [PubMed - indexed for MEDLINE]

Related Articles

Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes.

Tamemoto H, Ikoma A, Saitoh T, Ishikawa SE, Kawakami M.

Diabetes Technol Ther. 2007 Jun;9(3):246-53.

PMID: 17561795 [PubMed - indexed for MEDLINE]

Related Articles

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID: 16291411 [PubMed - indexed for MEDLINE]

Related Articles

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

Clin Ther. 2007 Nov;29(11):2333-48.

PMID: 18158075 [PubMed - indexed for MEDLINE]

Related Articles

Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group.

Zinman B, Ross S, Campos RV, Strack T.

Diabetes Care. 1999 Apr;22(4):603-8.

PMID: 10189539 [PubMed - indexed for MEDLINE]

Related Articles

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

[No authors listed]

Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602.

PMID: 9742976 [PubMed - indexed for MEDLINE]

Related Articles